Please upgrade your browser.
'Bullying, ignorant and patronising': NICE attacked by experts over drug ban scandal for cancer patients
The unprecedented attack follows the highly-controversial decision to ban drugs that can extend the life of kidney cancer victims.
Thousands of kidney cancer patients have been handed an 'early death sentence' under plans to ban life-extending new drugs.
Many of the drugs are used to treat rare ailments, such as Ovation Pharmaceuticals' Cosmegen, which is prescribed exclusively to children with rare kidney cancer. The company raised the drugs' price more than 3,400 percent in 2006 to $593.75 from just $16.79.
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients with selected advanced or recurrent solid tumors, specifically renal cell carcinoma, melanoma, non-small cell lung cancer or epithelial ovarian cancer. MDX-1105 is a fully human antibody that targets the PD-L1 pathway to promote enhanced T-cell immune responses against cancer and reverse T-cell inactivation in chronic infectious disease. Source: redorbit.com
LONDON, Aug 7 (Reuters) - Kidney cancer patients should not be treated with four expensive new medicines on Britain's state-run National Health Service, the country's health cost-effectiveness watchdog said on Thursday. The National Institute of Health and Clinical Excellence (NICE) said Roche's (ROG.VX: Quote, Profile, Research, Stock Buzz) Avastin, Bayer's (BAYG.DE: Quote, Profile, Research, Stock Buzz) Nexavar, Pfizer's (PFE.N: Quote, Profile, Research, Stock Buzz) Sutent and Wyeth's (WYE.N: Quote, Profile, Research, Stock Buzz) Torisel could extend patients' lives by some months but were not cost-effective.
Patients with advanced kidney cancer will be denied four treatments on the NHS under proposals from the government's drugs advisory body.
The reseaqrchers identified SDHB and SDHD as markers of CS susceptibility in people with normal PTEN. In fact, mutations in these genes confer a higher risk of breast, thyroid and kidney cancers than PTEN mutations for individuals with dysfunctional PTEN, the researchers said.
Kidney cancer patient Clive Stone has begged Health Secretary Alan Johnson to step in and halt the 'postcode lottery' over a life-extending drug. Mr Stone, from Freeland, near Witney, sent a letter to Mr Johnson about the refusal of Oxfordshire Primary Care Trust to give the drug Sunitinib to 20 patients, and asked the Government to intervene. Source: Oxford Mail
MOVE MORE, live longer. It sounds simple, but complex research shows folks who are more physically active have far lower rates of cancer. Even folks who already have cancer can benefit--people who exercise during cancer treatment feel better faster, studies prove
The center currently oversees 35 clinical trials, with about 50 patients in active drug therapies and about 200 in follow-up phases, said clinical trials coordinator Shelley Francella. One trial is studying two drugs used to treat metastatic kidney cancer, and a Middletown man who beat the cancer earlier this year is hoping his involvement will help himself and others. Source: FrederickNewsPost.com
|NeonCRM by Neon One|